A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
-
BUSINESS Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
June 14, 2022
-
REGULATORY MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
June 14, 2022
-
ORGANIZATION FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
-
REGULATORY “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
-
BUSINESS Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
June 9, 2022
-
BUSINESS Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
June 8, 2022
-
REGULATORY Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
June 8, 2022
-
REGULATORY Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
-
REGULATORY Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
-
REGULATORY Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
-
BUSINESS Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
June 3, 2022
-
COMMENTARY New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
June 2, 2022
-
BUSINESS Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
June 2, 2022
-
REGULATORY Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
-
BUSINESS Takeda to Transfer Spikevax Authorization to Moderna in Japan, 3-Way Purchase Deal to End
June 1, 2022
-
ACADEMIA NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
May 31, 2022
-
REGULATORY Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
-
BUSINESS Japan Drug Majors Expand Global Oncology Sales in FY2021
May 30, 2022
-
BUSINESS Moderna Eyes Bivalent Booster Rollout This Fall via Emergency Approval Path in Japan: CMO
May 30, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…